In a bold move that signals its growth and ambition, Ritedose has made a significant acquisition that elevates its status in the pharmaceutical industry. With this strategic purchase, the company now claims the title of the largest generic inhalation drug manufacturer of its kind—and the impact is already tangible across its operations. READ MORE
A Game-Changing Acquisition
Ritedose recently acquired the Arformoterol Tartrate asset from PAI Pharma, effectively expanding its inhalation drug portfolio and strengthening its foothold in the market. Before the acquisition, Arformoterol Tartrate (a generic equivalent of Brovana) had an estimated market of about $252 million in 2021. This inhalation therapy is used to help manage symptoms like shortness of breath, wheezing, and chest tightness in patients suffering from chronic obstructive pulmonary disease (COPD), which includes diseases like chronic bronchitis and emphysema.
By securing this asset, Ritedose has added a vital medication to its product line and positioned itself to serve more patients through healthcare channels across the U.S.
Why This Matters for Ritedose
This milestone is more than just a headline. It reflects years of investment, expertise, and strategic planning:
- Expanded product breadth: With Arformoterol Tartrate now under its umbrella, Ritedose boasts one of the most complete nebulized inhalation portfolios in the sector.
- Greater patient reach: More providers and patients can now rely on Ritedose to supply this critical respiratory medication.
- Validation of capabilities: The move underscores Ritedose’s strength in sterile, single-dose drug manufacturing and its ability to absorb and scale specialized inhalation assets.
- Momentum boost: Having delivered billions of doses in the past decade without interruption, these gains reinforce confidence among customers, partners, and investors.
Ritedose’s Backbone: Expertise, Infrastructure, and Vision
Ritedose has long specialized in aseptic production of sterile, single-dose medications—particularly using blow-fill-seal (BFS) technology. Over its history, the company has delivered billions of units to hospitals, retail pharmacies, wholesalers, and government agencies. Its campus in Columbia, South Carolina, is purpose-built for manufacturing, packaging, and distribution under rigorous quality and regulatory standards.
This organizational foundation makes it well-positioned to scale newly acquired products and ensure consistent supply and quality.
What’s Next: Growth, Innovation & Community Impact
The Arformoterol acquisition is just one piece of Ritedose’s broader roadmap:
- The company is actively expanding its capacity, both in manufacturing and logistics, to sustain higher volume demands.
- It is pursuing new product development and making strategic investments in facility upgrades, lab space, and packaging infrastructure.
- Community and workforce growth are also central—Ritedose continues to create jobs, partner with local institutions, and integrate sustainability and wellness features into its facilities.
Final Thoughts
Ritedose’s acquisition of a high-value inhalation drug asset is a defining moment. It cements its role not just as a generics manufacturer, but as a leading force in respiratory and inhalation therapy. Backed by decades of experience in sterile manufacturing and supported by a growing infrastructure and a clear vision, the company is now uniquely positioned to deliver more innovative, high-quality medications to patients in need.